2012
DOI: 10.1039/c2jm15277k
|View full text |Cite
|
Sign up to set email alerts
|

Reducible self-assembled micelles for enhanced intracellular delivery of doxorubicin

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

1
26
0

Year Published

2012
2012
2024
2024

Publication Types

Select...
9

Relationship

0
9

Authors

Journals

citations
Cited by 41 publications
(27 citation statements)
references
References 41 publications
1
26
0
Order By: Relevance
“…These micelles aggregated instead of disassociating after treatment with DTT for 7 days. A similar phenomenon was observed for disulfide‐containing PAE‐ graft ‐PEG (SS‐PAE‐ g ‐PEG) micelles 161. In PBS, these micelles were approximately 100 nm in size and were stable in the absence of DTT.…”
Section: Redox‐sensitive Polymeric Nanoparticlessupporting
confidence: 68%
“…These micelles aggregated instead of disassociating after treatment with DTT for 7 days. A similar phenomenon was observed for disulfide‐containing PAE‐ graft ‐PEG (SS‐PAE‐ g ‐PEG) micelles 161. In PBS, these micelles were approximately 100 nm in size and were stable in the absence of DTT.…”
Section: Redox‐sensitive Polymeric Nanoparticlessupporting
confidence: 68%
“…Nevertheless, micelles present the advantage of being more stable than liposomes (Andrade et al, 2011a). The versatility of micelles explains why they have been proposed as vehicles for solubilization and delivery of a variety of drugs like doxorubicin (Chen et al, 2012), paclitaxel (Kato et al, 2011;Lee et al, 2008), rifampicin (Moretton et al, 2013), calcitonin (Baginski et al, 2012), cyclosporine A (Di Tommaso et al, 2012) among others, being some formulations in clinical trials (Kato et al, 2011;Lee et al, 2008). Due to the development noted in the biotechnology field, biopharmaceuticals have emerged as an alternative to conventional drugs in the treatment of many diseases.…”
Section: Introductionmentioning
confidence: 99%
“…29,30 The work from different groups has demonstrated that reduction-responsive polymeric nanocarriers exhibit significantly improved in vitro and in vivo antitumor efficacy as compared to their reduction-insensitive counterparts. [31][32][33][34] The synthesis of reduction-responsive biocompatible and biodegradable polymeric systems, nevertheless, is not straightforward and often involves multiple steps. It should also be noted that to enhance their tumor specificity, cellular uptake and therapeutic efficacy, reduction-responsive biodegradable nanoparticles are additionally obliged to be equipped with specific targeting ligands.…”
Section: Introductionmentioning
confidence: 99%